

A Big Pharma update on Fighting Superbugs: GSK Report Industry Developments in Addressing AMR

SMi Reports: Superbugs & Superdrugs 2017 returns to Central London for its 19th Annual Show this March

LONDON, ENGLAND, UNITED KINGDOM, January 10, 2017 /EINPresswire.com/ -- SMi Group will welcome the expertise of James Anderson, Head of Corporate Affairs from GlaxoSmithKline, who will be providing attendees at the 19th annual <u>Superbugs and Superdrugs</u> show with an exclusive update on how the pharmaceutical industry is helping address anti-microbial resistance (AMR).

A recent report by Public Health England revealed that FEWER antibiotics are being prescribed by GPs and clinicians for the first time.* However there is still a lot of work to be done. What else is the industry doing beyond investing in R&D for new antibiotics?



The GSK keynote address will delve further into key topics surrounding partnerships with healthcare systems to ensure sterile manufacturing, antibiotic stewardship and new economic models for sustainable solutions.

He will be joined in London this March by a notable speaker line up including:

- Sumathi Nambiar, Director, Division of Anti-Infective Products, FDA
- Richard Bax, Senior Partner, TranScrip
- Lloyd Czaplewski, Director, Chemical Biology Ventures
- Chris Houchens, Branch Chief, BARDA
- Aileen Rubio, Head of Biology, Spero Therapeutics
- David Williams, Chief Executive Officer, Discuva
- Martin Everett, Chief Scientific Officer, ANTABIO SAS
- Jean de Gunzburg, Scientific Director, Da Volterra
- William J Weiss, Director, Pre-Clinical Services, UNT System College of Pharmacy
- Xavier Duportet, CEO, Eligo Bioscience

٢٢

In 2016 we may have witnessed change... Networking and learning with our peers is the secret to improving the drug development pipeline. Further details including a detailed conference agenda and full speaker line-up is available at www.superbugssuperdrugs.com

Superbugs & Superdrugs 2017 20TH & 21ST March Copthorne Tara Hotel, London, UK <u>http://www.superbugssuperdrugs.com/ein</u>

--end –

Joint statement from Transcript Partners and Chemical Biology Ventures

* Source: http://bit.ly/2fx6MtL

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For delegate enquires contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smionline.co.uk

For exhibition and sponsorship enquires contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group +442078276162 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.